CN102883746A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN102883746A
CN102883746A CN2011800232164A CN201180023216A CN102883746A CN 102883746 A CN102883746 A CN 102883746A CN 2011800232164 A CN2011800232164 A CN 2011800232164A CN 201180023216 A CN201180023216 A CN 201180023216A CN 102883746 A CN102883746 A CN 102883746A
Authority
CN
China
Prior art keywords
cell
vaccine
cancer
patient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800232164A
Other languages
English (en)
Chinese (zh)
Inventor
埃克哈德·R·波达克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of CN102883746A publication Critical patent/CN102883746A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2011800232164A 2010-05-21 2011-05-20 癌症治疗 Pending CN102883746A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34733610P 2010-05-21 2010-05-21
US61/347,336 2010-05-21
PCT/US2011/037327 WO2011146828A2 (en) 2010-05-21 2011-05-20 Cancer treatment

Publications (1)

Publication Number Publication Date
CN102883746A true CN102883746A (zh) 2013-01-16

Family

ID=44972662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800232164A Pending CN102883746A (zh) 2010-05-21 2011-05-20 癌症治疗

Country Status (9)

Country Link
US (1) US20110287057A1 (enExample)
EP (1) EP2571522A4 (enExample)
JP (1) JP2013526582A (enExample)
KR (1) KR20130113953A (enExample)
CN (1) CN102883746A (enExample)
AU (1) AU2011255463A1 (enExample)
CA (1) CA2837059A1 (enExample)
IL (1) IL222958A0 (enExample)
WO (1) WO2011146828A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027915A1 (zh) * 2013-09-02 2015-03-05 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3720450A4 (en) * 2017-12-04 2021-07-28 Heat Biologics, Inc. CELL-BASED VACCINE PRODUCTION
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006413A1 (en) * 2000-01-27 2002-01-17 Sobol Robert E. Genetically engineered tumor cell vaccines
EP1667701A4 (en) * 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
US8475785B2 (en) * 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PODACK ET AL.: "Immunotherapy for lung tumors: M17-01", 《JOURNAL OF THORACIC ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027915A1 (zh) * 2013-09-02 2015-03-05 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
US10980859B2 (en) 2013-09-02 2021-04-20 Hangzhou Converd Co., Ltd. In vivo individualized systemic immunotherapeutic method and device

Also Published As

Publication number Publication date
AU2011255463A1 (en) 2012-11-01
EP2571522A4 (en) 2013-11-20
CA2837059A1 (en) 2011-11-24
JP2013526582A (ja) 2013-06-24
WO2011146828A3 (en) 2012-03-15
EP2571522A2 (en) 2013-03-27
WO2011146828A2 (en) 2011-11-24
KR20130113953A (ko) 2013-10-16
US20110287057A1 (en) 2011-11-24
IL222958A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
CN102883746A (zh) 癌症治疗
Chodon et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma
Okada et al. Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
Batich et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination
Phuphanich et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Hirschowitz et al. Autologous dendritic cell vaccines for non–small-cell lung cancer
Sarivalasis et al. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
Jaffee et al. A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland
Chen et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF–secreting breast tumor vaccine for HER2+ metastatic breast cancer
Okada et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
Okada et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC
Nemunaitis et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer
Bolonaki et al. Vaccination of patients with advanced non–small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide
Dillman et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma
Zandberg et al. A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
US20120164099A1 (en) Use of human prostate cell lines in cancer treatment
Olivares et al. Phase I trial of TGF-β2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine
Mackiewicz et al. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection
Sharma et al. CCL21 chemokine therapy for lung cancer
Hickey et al. Cellular and vaccine therapeutic approaches for gliomas
Pu et al. Immunotherapy for recurrent glioma—From bench to bedside
EP0721351A1 (en) Haplotype-matched cytokine-secreting cells and methods of using to stimulate an immune response
US20050019336A1 (en) Human prostate cell lines in cancer treatment
JP5079962B2 (ja) ＴＧＦβ阻害剤を発現する遺伝的に改変された細胞であって、肺癌細胞である細胞
Manning et al. Assessment of low dose Vigil® engineered autologous tumor cell (EATC) immunotherapy in patients with advanced solid tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180216

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130116

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1180216

Country of ref document: HK